Press release
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq: INCY) today announced that several abstracts featuring data from its oncology portfolio will be presented
About this update from Incyte Corporation
[{"type":"text","content":" WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq: INCY) today announced that several abstracts featuring data from its oncology portfolio will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held May 31 – June 4 in Chicago, and at the European Hematology Association 2024 (EHA2024) Congress held on June 13-16 in Madrid, Spain, and virtually.\n\n\n\"The data being presented at ASCO and EHA demonstrates Incyte’s dedication to our comprehensive research approach to identifying new first and best in class treatments for cancer patients,\" stated Steven Stein, M.D., Chief Medical Officer at Incyte. \"The research we're presenting emphasizes promise within our oncology pipeline in areas where there is a continued need for therapeutic development across a breadth of cancers.\"\n\n\nKey abstracts accepted for presentation at ASCO and EHA include:\n\n\nASCO Abstracts\n\n\nAbstracts will be available to registered attendees on the ASCO Congress platform beginning on May 23, 2024. Posters and slides will be available to registered attendees at the scheduled session start time.\n\n\nPoster Presentations\n\n\nINCB099280\n\n\nA Phase 1 study of the Small-Molecule PD-L1 inhibitor INCB099280 in Select Advanced Solid Tumors: Updated Safety, Efficacy, and Pharmacokinetics (PK) Results (Abstract #2608. Session: Developmental Therapeutics—Immunotherapy. Saturday, June 1, 9:00 a.m. -12:00 p.m. ET)\n\n\nINCB057643\n\n\nBromodomain and Extra-Terminal (BET) Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis (MF) and Other Advanced Myeloid Neoplasms: A Phase 1 Study (Abstract #6576. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant. Monday, June 3, 9:00 a.m.-12:00 p.m. ET)\n\n\nEHA Abstracts\n\n\nAbstracts are available on the EHA2024 Congress platform and accessible for on-demand viewing until August 15, 2024.\n\n\nOral Presentations\n\n\nRuxolitinib\n\n\nAnalysis of Molecular Mechanisms and Predictive Biomarkers of Disease Transformation in Polycythemia Vera (Abstract #S217. Topic: Myeloproliferative Neoplasms – Biology & Translational Research. Friday, June 14, 8:45 a.m. – 10:00 a.m. ET)\n\n\nPoster Presentations\n\n\nRuxolitinib\n\n\nA Real-World Evaluation of Risk Factors for Disease Progression in Patients With Polycythemia Vera (PV) En...